Results 41 to 50 of about 2,272 (175)

Early Clinical Response of a Large Amebic Liver Abscess to Eravacycline Prior to Metronidazole Initiation: A Case Report. [PDF]

Case Rep Infect Dis
Entamoeba histolytica is an amebic protozoan that is often asymptomatic, with many patients being asymptomatic carriers. However, 10 percent of cases manifest with amebic dysentery and, less commonly, amebic liver abscesses. Amebic liver abscesses are the most common extraintestinal manifestation of E. histolytica.
Anthony JA, Robinson A, Pedroza L.
europepmc   +2 more sources

In vitro activity of eravacycline against common ribotypes of Clostridioides difficile [PDF]

, 2020
Background Eravacycline is a novel synthetic fluorocycline antibacterial approved for complicated intra-abdominal infections. Objectives The purpose of this study was to assess the in vitro activities of eravacycline and comparator antibiotics against ...
Miranda, Julie, Carlson, Travis J, Gonzales-Luna, Anne J, Garey, Kevin W, Wilcox, Mark H, Bassères, Eugénie, Alam, M Jahangir, Rashid, Tasnuva, Lancaster, Chris, Begum, Khurshida, Eyre, David W   +10 more
core   +1 more source

Eravacycline Associated Hypofibrinogenemia: A Case Series of Transplant Patients With Mycobacterium Abscessus Infections and Review of Literature [PDF]

, 2022
Eravacycline is a synthetic fluorocycline within the tetracycline class of antimicrobials. Eravacycline is active in vitro against several clinically important Gram-positive and Gram-negative bacteria.
Marx A., Rausch E., Andermann T.M., Daniels L., Fabricio J., Bartelt L.A., Van Duin D., Lachiewicz A., Vemuri K., Seña A.C.   +9 more
core   +1 more source

Overexpression of OqxAB and MacAB efflux pumps contributes to eravacycline resistance and heteroresistance in clinical isolates of Klebsiella pneumoniae

Emerging Microbes and Infections, 2018
This study investigated the characteristics and mechanisms of eravacycline resistance and heteroresistance in clinical Klebsiella pneumoniae isolates. A total of 393 clinical K.
Jin-xin Zheng, Zhi-wei Lin, Xiang Sun, Wei-hong Lin, Zhong Chen, Yang Wu, Guo-bin Qi, Qi-wen Deng, Di Qu, Zhi-jian Yu   +9 more
doaj   +1 more source

AdeABC Efflux Pump Controlled by AdeRS Two Component System Conferring Resistance to Tigecycline, Omadacycline and Eravacycline in Clinical Carbapenem Resistant Acinetobacter nosocomialis

Frontiers in Microbiology, 2020
Carbapenem-resistant Acinetobacter nosocomialis (CRAn) is a significant public health concern. Tigecycline non-susceptible CRAn (Tn-CRAn) isolates have emerged worldwide.
Yi-Tzu Lee, Yi-Tzu Lee, Hsing-Yu Chen, Ya-Sung Yang, Yu-Ching Chou, Tein-Yao Chang, Wei-Jane Hsu, I-Chieh Lin, ACTION Study Group, Jun-Ren Sun   +9 more
doaj   +1 more source

Early Experience With Eravacycline for Complicated Infections [PDF]

Open Forum Infectious Diseases, 2020
Abstract Eravacycline (ERV) was used in 35 patients for various infections. The most common pathogen was Klebsiella pneumoniae, and 30-day survival was 74%. Absence of 30-day recurrence and resolution of signs and symptoms of infection were 91% and 57%, respectively.
Sara, Alosaimy, Kyle C, Molina, Kimberly C, Claeys, Justin, Andrade, James, Truong, Madeline A, King, Benjamin M, Pullinger, Glen, Huang, Taylor, Morrisette, Abdalhamid M, Lagnf, Susan L, Davis, Michael J, Rybak   +11 more
openaire   +2 more sources

Eravacycline in Critically Ill Patients with Multidrug-Resistant Gram-Negative Infections: A Real-World Cohort Study. [PDF]

J Clin Med
Background: Multidrug-resistant Gram-negative infections remain a major challenge in critically ill patients, particularly when caused by carbapenem-resistant pathogens with limited therapeutic options.
Ritiu SA, Baloi A, Papurica M, Sandesc D, Toma D, Popovici SE, Barsac CR, Butaș M, Botoaca AM, Bedreag OH.   +9 more
europepmc   +2 more sources

In Vitro Activities of Aztreonam-Avibactam, Eravacycline, Cefoselis, and Other Comparators against Clinical Enterobacterales Isolates: a Multicenter Study in China, 2019

Microbiology Spectrum, 2023
Aztreonam-avibactam, eravacycline, and cefoselis are three novel antimicrobial agents for the treatment of serious infections caused by Gram-negative bacteria. We evaluated the in vitro activities of the above-mentioned three antimicrobial agents against
Jiawei Chen, Yong Liu, Wei Jia, Xuesong Xu, Guizhen Sun, Tong Wang, Jin Li, Ge Zhang, Ran Jing, Hongli Sun, Yingchun Xu, Yali Liu   +11 more
doaj   +1 more source

1243. Eravacycline in Bacteremia: A Case Series [PDF]

Open Forum Infectious Diseases, 2021
Abstract Background Eravacycline (ERV) is FDA-approved for the treatment of complicated intra-abdominal infections, but there is limited experience for non-FDA approved indications. Methods We present five cases that utilized ERV for ...
Andrade, Justin A, Kosalka, Robert, Truong, James, Rosenberg, Joshua R   +3 more
openaire   +1 more source

In vitro antibacterial activity of eravacycline against multidrug-resistant Acinetobacter baumannii isolates

, 2021
The antibacterial effectiveness of eravacycline was compared with various antibiotics used in Acinetobacter therapy against multidrug-resistant (MDR) Acinetobacter baumannii strains.
Ataman, Merve, Mataraci-Kara, Emel, Ozbek-Celik, Berna   +2 more
core   +1 more source